News

Article

Xellia Pharmaceuticals Officially Opens New Anti-Infective Drug Products Manufacturing Site

The Cleveland, Ohio facility will produce critical anti-infective drug products for US hospitals.

Xellia Pharmaceuticals, a pharmaceutical manufacturer specializing in anti-infective treatments, announced that its manufacturing site in Cleveland, Ohio is now commercially operational. The company has released the first anti-infectives manufactured at the site for distribution to US hospitals.

As part of their vertical integration strategy, Xellia plans to continuously expand the capabilities of this site. For example, in addition to commencing commercial supply, the facility is also preparing ramp-up of its newly installed aseptic bag manufacturing line.

Xellia bought the Cleveland site in 2015 and has significantly renovated it since then. It passed a comprehensive Current Good Manufacturing Practices (CGMP) test by FDA in 2020. The facility currently employs over 300 individuals.

“The release of the first commercial product manufactured at our Cleveland facility is a significant milestone for Xellia,” said Carl-Ake Carlsson, CEO and president of Xellia Pharmaceuticals, in a company press release. “We acquired the site to fulfil an ambition to provide US hospitals and patients with critical care products made locally. We are proud to be producing high quality, key anti-infectives and we look forward to working with more partners who are aligned with Xellia’s purpose to save patient lives.”

Source: Xellia Pharmaceuticals

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content